Coqui RadioPharmaceuticals Signs Contract with INVAP

Coqui RadioPharmaceuticals Corp. announced that it has signed a contract with INVAP SE regarding the design of its medical isotope production facility, which is to be located in Alachua, Florida.

Coqui is working to become the first commercial of molybdenum-99 in the United States.

As quoted in the press release:

Argentine nuclear engineering firm INVAP has been involved in nuclear development for more than 30 years. During that time it has worked on more than 15 nuclear reactors and related facilities across the world, including several reactors used to produce medical isotopes. Among these is the OPAL reactor in Australia, the ETRR-2 reactor in Egypt, and the NUR reactor in Algeria. Coqui Pharma’s MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia.

Carmen I. Bigles, president and CEO of Coqui, commented:

The signing of this contract cements a key step in implementing proven technology to produce Mo-99 for patients requiring lifesaving medical diagnostics. Today, Coqui Pharma together with INVAP has built a bridge between the U.S. and Argentina, uniting our efforts to ensure the availability and reliability of the most essential radioisotope in nuclear medicine and with the added benefit of making the world a safer place for generations to come by utilizing proven non-proliferation, low-enriched uranium technologies.

Click here to read the full Coqui RadioPharmaceuticals Corp. press release.
Click here to read an interview with Carmen Bigles.